GI well being platform Vivante Well being secures $31M

Digital gastrointestinal well being firm Vivante Health introduced it closed a $31 million Sequence B funding spherical led by new investor Mercato Companions, bringing its whole elevate to $47 million.

Well being Catalyst, Intermountain Ventures, SemperVirens, 7wireVentures, Human Capital and Distributed Ventures participated within the spherical. 

WHAT IT DOES

Vivante presents a platform dubbed GIThrive that gives personalised care plans. Sufferers can observe their signs and entry instructional content material and self-guided behavioral well being modules. A coordinated crew of suppliers can be out there by way of the platform, together with dietitians, coaches and well being physicians.

The Illinois-based firm will use the funding to improve its know-how and broaden its workforce.  

“We’re thrilled to have the assist of industry-leading capital companions as we execute on our imaginative and prescient at Vivante,” Invoice Snyder, Vivante Well being CEO, stated in a press release. “One in 4 Individuals suffers from a digestive dysfunction or undiagnosed digestive signs that have an effect on their high quality of life in addition to their healthcare prices. We’ve got confirmed that our scalable know-how platform paired with our complete care crew leads to higher well being, decrease prices and a significantly better expertise for the members we serve.”

MARKET SNAPSHOT

Vivante raised $16 million in Series A funding final 12 months, $5.8 million in Series A1 investment in 2020 and $6 million in 2018. 

In 2022, Solera Health, a digital platform that provides a market for advantages and persistent illness administration packages, announced it was adding Vivante and fellow digital gastrointestinal well being firm Oshi Health to its market of advantages and persistent care administration instruments. 

Different corporations within the digital gastrointestinal house embody Salvo Health, which presents a digital clinic geared towards individuals with persistent intestine issues comparable to irritable bowel syndrome, and Bold Health, a London-based firm creating digital therapeutics for gastrointestinal situations.